Room for improvement in the treatment of generalized anxiety disorder
Room for improvement in the treatment of generalized anxiety disorder
Generalized anxiety disorder (GAD) is a common and debilitating medical condition, associated with significant social and occupational impairment, and is traditionally thought to run a chronic course, waxing and waning in severity. A range of pharmacological treatments for patients with GAD are available, including certain selective serotonin reuptake inhibitors (SSRI), the serotonin-noradrenaline reuptake inhibitors (SNRI) venlafaxine and duloxetine, some benzodiazepines, and the novel anticonvulsant and anxiolytic drug, pregabalin. The
conventional neuroleptic trifluoperazine has been found efficacious in acute treatment and the second generation antipsychotic drugs risperidone and olanzapine have been found helpful in placebo-controlled augmentation studies in patients responding only poorly to initial treatment with an SSRI (Baldwin & Polkinghorn, 2005).
generalized anxiety disorder
309-309
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
2007
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Baldwin, D.S.
(2007)
Room for improvement in the treatment of generalized anxiety disorder.
International Journal of Psychiatry in Clinical Practice, 11 (4), .
Abstract
Generalized anxiety disorder (GAD) is a common and debilitating medical condition, associated with significant social and occupational impairment, and is traditionally thought to run a chronic course, waxing and waning in severity. A range of pharmacological treatments for patients with GAD are available, including certain selective serotonin reuptake inhibitors (SSRI), the serotonin-noradrenaline reuptake inhibitors (SNRI) venlafaxine and duloxetine, some benzodiazepines, and the novel anticonvulsant and anxiolytic drug, pregabalin. The
conventional neuroleptic trifluoperazine has been found efficacious in acute treatment and the second generation antipsychotic drugs risperidone and olanzapine have been found helpful in placebo-controlled augmentation studies in patients responding only poorly to initial treatment with an SSRI (Baldwin & Polkinghorn, 2005).
This record has no associated files available for download.
More information
Published date: 2007
Keywords:
generalized anxiety disorder
Identifiers
Local EPrints ID: 62275
URI: http://eprints.soton.ac.uk/id/eprint/62275
PURE UUID: 71a301a7-0a28-416e-8973-7d3d4436d4b9
Catalogue record
Date deposited: 04 Sep 2008
Last modified: 12 Dec 2021 02:52
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
